Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Suspended 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Basal Cell Nevus Syndrome 3Carcinoma, Basal Cell 2Skin Neoplasms 1Lymphoma, Follicular 1Lupus Erythematosus, Systemic 1

Interventions

HhAntag691 21Biopsy 11Imiquimod 10Aminolevulinic Acid 9sonidegib 8Photochemotherapy 8Nivolumab 81-phenyl-3,3-dimethyltriazene 7methyl 5-aminolevulinate 6cemiplimab 6Surgical Procedures, Operative 5Specimen Handling 5Radiotherapy 5Itraconazole 5pembrolizumab 4daromun 4Mohs Surgery 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Curettage 4Tomography, Optical Coherence 3Standard of Care 3Niacinamide 3Microscopy, Confocal 3IPI-926 3CTLA-4 Antigen 33-ingenyl angelate 3tazarotene 2talimogene laherparepvec 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Basal Cell × gusacitinib × Clear all
NCT04416516 2024-04-10

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Ascend Biopharmaceuticals Ltd

Phase 2 Completed
21 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT03208296 2023-02-06

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Ascend Biopharmaceuticals Ltd

Phase 1/2 Suspended
24 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡